Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Published in: The Lancet Haematology
Access to document
10.1016/S2352-3026(23)00279-X
document
Background: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens. Methods: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland. Eligible patients were aged 18–75 years with newly diagnosed high-risk Burkitt lymphoma without CNS involvement. Patients were randomly assigned to two cycles of R-CODOX-M/R-IVAC (R-CODOX-M: rituximab 375 mg/m2 on day...
Martine E.D. Chamuleau, Frank Stenner, Dana A. Chitu, Urban Novak, Monique C. Minnema, Paul Geerts, Wendy B.C. Stevens, Thorsten Zenz, Gustaaf W. van Imhoff, Ka Lung Wu, Astrid M.P. Demandt, Marie Jose Kersten, Wim E. Terpstra, Lidwine W. Tick, Dries Deeren, Eric Van Den Neste, Michael Gregor, Hendrik Veelken, Lara H. Böhmer, Clemens B. CasparPim Mutsaers, Jeannine M. Refos, Robby Sewsaran, Liping Fu, Rianne L. Seefat, Carin A. Uyl-de Groot, Stefan Dirnhofer, Michiel Van Den Brand, Daphne de Jong, Marcel Nijland, Pieternella Lugtenburg
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome
Published in: Rheumatology
Access to document
10.1093/rheumatology/kead071
document
OBJECTIVES: To assess the usefulness of FDG-PET/CT 1) to discriminate between pSS patients with and without lymphomas and 2) to evaluate systemic disease activity in pSS. METHODS: ACR-EULAR-positive pSS patients who underwent FDG-PET/CT were included. Scans were visually evaluated and quantitative analysis was performed by measuring standardized uptake values (SUV) of salivary and lacrimal glands and systemic regions. ROC analyses were performed to find SUV cut-off values to discriminate between lymphoma and non-lymphoma. RESULTS: 26 of the 70 included patients were diagnosed with a pSS-associated lymphoma, mostly of...
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
Published in: Blood
Access to document
10.1182/blood.2023020195
document
Chronic lymphocytic leukemia (CLL)–related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67). However, prolonged venetoclax exposure as consolidation treatment led to increased...
HOVON CLL Working Group, Lina van der Straten, Claudia A.M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H.M. Mellink, Anne Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F.M. PosthumaHein P.J. Visser, I. Houtenbos, Cecile A.M. Idink, D. E. Issa, Ellen C. Dompeling, Henk C.T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, A. P. Kater, Mark David Levin
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Published in: Journal of Hematology and Oncology
Access to document
10.1186/s13045-023-01500-x
document
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic PTLD after solid organ transplantation in this multi-center observational cohort study. We used low-coverage whole genome sequencing (lcWGS) to detect copy number variations (CNVs) and targeted next-generation sequencing (NGS) to identify...
Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A.A. Bult, Martijn M. Terpstra, Pim G.N.J. Mutsaers, Wendy B.C. Stevens, Rogier Mous, Joost S.P. Vermaat, Martine E.D. Chamuleau, Walter Noordzij, Erik A.M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Published in: Blood cancer journal
Access to document
10.1038/s41408-023-00903-w
document
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL...
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland